This new AI tool can detect 9 types of dementia from single brain scan
The tool, StateViewer, not only helped in early detection but also provided accurate diagnosis -- it identified the dementia type in 88 per cent of cases, including Alzheimer's disease.
It also enabled clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows, according to the research, published online in the journal Neurology.
Researchers from the Mayo Clinic trained and tested the AI on more than 3,600 scans, including images from patients with dementia and people without cognitive impairment.
Currently, diagnosing dementia requires cognitive tests, blood draws, imaging, and clinical interviews, and yet, distinguishing conditions such as Alzheimer's, Lewy body dementia and frontotemporal dementia remains a challenge.
'Every patient who walks into my clinic carries a unique story shaped by the brain's complexity,' said David Jones, a Mayo Clinic neurologist.
'StateViewer reflects that commitment -- a step toward earlier understanding, more precise treatment, and, one day, changing the course of these diseases,' added Jones, director of the Mayo Clinic Neurology Artificial Intelligence Programme.
The tool analyses a fluorodeoxyglucose positron emission tomography (FDG-PET) scan, which shows how the brain uses glucose for energy. It then compares the scan to a large database of scans from people with confirmed dementia diagnoses and identifies patterns that match specific types, or combinations, of dementia.
While Alzheimer's affects memory and processing regions, Lewy body dementia involves areas tied to attention and movement. Frontotemporal dementia alters regions responsible for language and behaviour.
StateViewer displays these patterns through colour-coded brain maps that highlight key areas of brain activity, giving all clinicians, even those without neurology training, a visual explanation of what the AI sees and how it supports the diagnosis.
Dementia affects more than 55 million people worldwide, with nearly 10 million new cases each year. Alzheimer's disease, the most common form, is now the fifth-leading cause of death globally.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
5 hours ago
- Hindustan Times
No Alzheimer's Drug for Old Men?
Increasing evidence shows that anti-amyloid Alzheimer's treatments can slow disease progression and give patients years more of quality time with loved ones. So will the Trump Administration at long last drop the Biden rules that restrict access to these medicines? Two studies presented at the Alzheimer's Association International Conference last week show that the benefits of amyloid-clearing monoclonal antibodies by Eli Lilly and Biogen-Eisai grow over time. The drugs slowed cognitive decline in clinical trials used for Food and Drug Administration approval by some 25% to 36% over 18 months. In follow-up studies, these benefits doubled at three years for Lilly's treatment and roughly quadrupled over four years for Biogen-Eisai's. That's great news for patients. The findings are especially notable because critics argued for limiting Medicare coverage of the drugs on grounds that their benefits might not be durable. They dismissed the entire class of anti-amyloid drugs because earlier experimental treatments failed in trials. But trial and error often lead to discovery. Roche last week presented promising trial data on its experimental amyloid-clearing antibody. Roche and other drug makers also plan to test whether such treatments can prevent Alzheimer's. In an unprecedented move, the Biden Centers for Medicare and Medicaid Services (CMS) in 2022 restricted access to all anti-amyloid drugs approved by the FDA because it wasn't convinced they were 'reasonable and necessary.' As a result, Alzheimer's patients who want the treatments—and doctors who want to prescribe them—must jump through bureaucratic hoops. The Biden CMS claimed such restrictions were necessary to obtain more evidence of treatment benefits, though the agency had never before limited access in this way for an FDA-approved drug. Seventy-four House Members, including 38 Democrats, in 2023 urged CMS to remove its restrictions. As did 23 state Attorneys General. Medicare's coverage restrictions create 'a barrier to care for older Americans, especially individuals living in rural and underserved areas,' the AGs wrote. The Biden CMS remained unmoved. The new studies provide more evidence and cause for CMS Administrator Mehmet Oz to reverse course. Alzheimer's patients deserve a right to try too.
Economic Times
7 hours ago
- Economic Times
Alzheimer's symptoms and memory loss reverses by lithium supplement, offering new hope for cure
A Harvard Medical School study reveals that lithium orotate supplementation effectively reverses Alzheimer's-like memory loss and brain pathology in mice. The research highlights lithium depletion in Alzheimer's brains due to amyloid plaque binding. Supplementation restores lithium levels, reduces plaque burden, and improves cognitive function, offering a promising therapeutic avenue for Alzheimer's disease. Tired of too many ads? Remove Ads Understanding Alzheimer's and the role of lithium What the study found: Lithium depletion in Alzheimer's Tired of too many ads? Remove Ads How lithium deficiency affects the brain Healthy mice deprived of lithium showed early signs of brain aging, increased inflammation, and the formation of amyloid plaques and tau pathology. Alzheimer's-model mice on a lithium-deficient diet experienced a more rapid buildup of plaques, worsened memory decline, and impaired function of microglia, reducing the brain's ability to clear toxic proteins. The revolutionary solution: Lithium orotate supplement Alzheimer's mice treated with lithium orotate showed up to a 70% reduction in amyloid plaque burden. Memory tests revealed treated mice regained significant cognitive abilities, performing tasks they previously failed. Crucially, the lithium orotate supplement did not show toxic effects at the doses used, suggesting it could be safe for long-term use. Why this matters From mice to humans A groundbreaking study from Harvard Medical School , published in Nature , has unveiled that lithium orotate supplementation can reverse Alzheimer's-like memory loss and brain pathology in mice, suggesting a promising new therapeutic cure for this devastating neurodegenerative disease affecting around 55 million people disease, a progressive brain disorder characterized by memory loss and cognitive decline, has long eluded curative disease is marked by the accumulation of toxic proteins in the brain — primarily amyloid beta plaques and tau tangles — that disrupt neuron function and trigger inflammation. This causes neurons to die over time, leading to memory loss and cognitive is a naturally occurring mineral that has been used for decades in psychiatric medicine, especially to treat bipolar disorder. Importantly, lithium also supports essential cellular processes in the brain, helping to regulate signaling pathways, reduce oxidative stress, and protect neurons from new research uncovers a previously unknown problem: in the brains of individuals with Alzheimer's, lithium levels drop significantly. This happens because amyloid beta plaques physically bind lithium ions, sequestering them away from neurons and other brain cells that need lithium to function lithium is trapped inside plaques, nearby neurons and microglia — the brain's immune cells responsible for clearing out waste proteins — become lithium-deficient. This deficiency worsens plaque buildup and disrupts brain cleanup mechanisms, accelerating disease understand the impact, researchers studied mice with genetic modifications that cause Alzheimer's-like symptoms. They experimented with diets lacking lithium and observed that:This strongly suggested lithium deficiency is not just a side effect but an active driver of disease scientists then tested whether supplementing lithium could reverse these problems. They used a compound called lithium orotate, which is chemically structured to bypass the plaque sequestration that traps regular lithium salts, allowing lithium to effectively reach and nourish brain results were striking:Previous Alzheimer's treatments have largely focused on removing amyloid plaques or targeting other symptoms without restoring brain cell health. This new approach suggests that restoring lithium levels directly supports the brain's natural defense and repair systems, allowing neurons and immune cells to function normally and remove toxic since lithium is a naturally occurring nutrient found in food, water, and already used medically, translating these findings into human trials could be faster and more cost-effective compared to developing entirely new these findings are highly promising, scientists emphasize that more research is needed to determine if lithium orotate will have the same benefits and safety in people with Alzheimer's. Clinical trials are required to find optimal dosing, evaluate long-term effects, and understand potential these results translate to humans, we could see more accessible, affordable, and safe treatments emerging, potentially transforming the outlook for millions suffering from this devastating disease.
Time of India
7 hours ago
- Time of India
Alzheimer's symptoms and memory loss reverses by lithium supplement, offering new hope for cure
Understanding Alzheimer's and the role of lithium What the study found: Lithium depletion in Alzheimer's Live Events How lithium deficiency affects the brain Healthy mice deprived of lithium showed early signs of brain aging, increased inflammation, and the formation of amyloid plaques and tau pathology. Alzheimer's-model mice on a lithium-deficient diet experienced a more rapid buildup of plaques, worsened memory decline, and impaired function of microglia, reducing the brain's ability to clear toxic proteins. The revolutionary solution: Lithium orotate supplement Alzheimer's mice treated with lithium orotate showed up to a 70% reduction in amyloid plaque burden. Memory tests revealed treated mice regained significant cognitive abilities, performing tasks they previously failed. Crucially, the lithium orotate supplement did not show toxic effects at the doses used, suggesting it could be safe for long-term use. Why this matters From mice to humans (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel A groundbreaking study from Harvard Medical School , published in Nature , has unveiled that lithium orotate supplementation can reverse Alzheimer's-like memory loss and brain pathology in mice, suggesting a promising new therapeutic cure for this devastating neurodegenerative disease affecting around 55 million people disease, a progressive brain disorder characterized by memory loss and cognitive decline, has long eluded curative disease is marked by the accumulation of toxic proteins in the brain — primarily amyloid beta plaques and tau tangles — that disrupt neuron function and trigger inflammation. This causes neurons to die over time, leading to memory loss and cognitive is a naturally occurring mineral that has been used for decades in psychiatric medicine, especially to treat bipolar disorder. Importantly, lithium also supports essential cellular processes in the brain, helping to regulate signaling pathways, reduce oxidative stress, and protect neurons from new research uncovers a previously unknown problem: in the brains of individuals with Alzheimer's, lithium levels drop significantly. This happens because amyloid beta plaques physically bind lithium ions, sequestering them away from neurons and other brain cells that need lithium to function lithium is trapped inside plaques, nearby neurons and microglia — the brain's immune cells responsible for clearing out waste proteins — become lithium-deficient. This deficiency worsens plaque buildup and disrupts brain cleanup mechanisms, accelerating disease understand the impact, researchers studied mice with genetic modifications that cause Alzheimer's-like symptoms. They experimented with diets lacking lithium and observed that:This strongly suggested lithium deficiency is not just a side effect but an active driver of disease scientists then tested whether supplementing lithium could reverse these problems. They used a compound called lithium orotate, which is chemically structured to bypass the plaque sequestration that traps regular lithium salts, allowing lithium to effectively reach and nourish brain results were striking:Previous Alzheimer's treatments have largely focused on removing amyloid plaques or targeting other symptoms without restoring brain cell health. This new approach suggests that restoring lithium levels directly supports the brain's natural defense and repair systems, allowing neurons and immune cells to function normally and remove toxic since lithium is a naturally occurring nutrient found in food, water, and already used medically, translating these findings into human trials could be faster and more cost-effective compared to developing entirely new these findings are highly promising, scientists emphasize that more research is needed to determine if lithium orotate will have the same benefits and safety in people with Alzheimer's. Clinical trials are required to find optimal dosing, evaluate long-term effects, and understand potential these results translate to humans, we could see more accessible, affordable, and safe treatments emerging, potentially transforming the outlook for millions suffering from this devastating disease.
